Previous 10 | Next 10 |
Hancock Jaffe Laboratories ( HJLI +0.8% ) prices $5.6M offering , which includes underwritten public offering and private placement of units. More news on: Hancock Jaffe Laboratories, Inc., Healthcare stocks news, , Read more ...
IRVINE, CA / ACCESSWIRE / July 17, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a $5.6 million offering, which consisted of an underwritten public offering of units and a priva...
Hancock Jaffe Laboratories ( HJLI +24.3% ) has entered into a securities purchase agreement to purchase ~$1.33M of its common stock in a registered and direct offering and warrants to purchase shares in a concurrent private placement. More news on: Hancock Jaffe Laboratories,...
IRVINE, CA / ACCESSWIRE / June 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional investor...
Companies Sign Non-Binding Letter of Intent to Merge IRVINE, CA / ACCESSWIRE / June 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has signed a non-binding letter of in...
CoreoGraft Study Approved by the Superintendent of Health of the National Health Council of Paraguay IRVINE, CA / ACCESSWIRE / May 12, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that ...
VenoValve Patients Continue to Show Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / April 28, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that five VenoV...
IRVINE, CA / ACCESSWIRE / April 27, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional invest...
Updated VenoValve data will include 8 Patients at 180 days - including 1 Patient at 365 Days Post VenoValve Surgery IRVINE, CA / ACCESSWIRE / February 26, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular hea...
Grafts Open and Fully Functional at 6 Months IRVINE, CA / ACCESSWIRE / January 8, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced positive results from its six (6) month CoreoGraft animal f...
News, Short Squeeze, Breakout and More Instantly...
Hancock Jaffe Laboratories Inc. Company Name:
HJLI Stock Symbol:
NASDAQ Market:
Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully comple...
Live webinar followed by Q&A on Monday, September 27 th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medic...
- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the VenoValve® - - Initiated development of second product for the treatment of veno...